Your session is about to expire
← Back to Search
18F-MK-6240 for Alzheimer's Disease
Phase 2
Waitlist Available
Led By William Kreisl, MD
Research Sponsored by William Charles Kreisl
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age 50 and older.
Meet criteria for either
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to one year from screening.
Awards & highlights
Study Summary
This trial is measuring the amount of tau protein in the brain to see if it's linked to Alzheimer's disease.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to one year from screening.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to one year from screening.
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
18F-MK-6240 binding
Secondary outcome measures
Correlation between tau, neurodegeneration and inflammation using PET and CSF biomarkers.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Cognitive impairmentExperimental Treatment2 Interventions
Alzheimer's disease (mild cognitive impairment or mild stage Alzheimer's disease dementia)
Group II: No cognitive impairmentActive Control2 Interventions
Healthy controls
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
18F-MK-6240
2019
Completed Phase 2
~220
Lumbar Puncture (optional)
2017
Completed Phase 2
~80
Find a Location
Who is running the clinical trial?
William Charles KreislLead Sponsor
6 Previous Clinical Trials
481 Total Patients Enrolled
James M Noble, MD, MS, CPH, FAANLead Sponsor
2 Previous Clinical Trials
200 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,658 Previous Clinical Trials
28,004,374 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger